Synergistic antitumor effect of oroxylin A and donafenib in hepatocellular carcinoma through tumor protein p53 signaling pathway activation

Figure 2 Synergistic anti-proliferative and pro-apoptotic effects of oroxylin A and donafenib on hepatocellular carcinoma cells. A and B: The half-maximal inhibitory concentrations (IC₅₀) of oroxylin A (A) and donafenib (B) were determined in MHCC-97H and PLC-PRF-5 cell lines; C-E: MHCC-97H and PLC-PRF-5 cell proliferation were detected using Cell Counting Kit-8 assay (C) and colony formation assay (D and E) after treatment with oroxylin A and/or donafenib; F and G: Cell apoptosis was assessed using flow cytometry after treatment with oroxylin A and/or donafenib in MHCC-97H (F) and PLC-PRF-5 (G) cell lines. Data are presented as mean ± SD. ^bP < 0.01, ^cP < 0.001, ^dP < 0.0001. DMSO: Dimethyl sulfoxide; OA: Oroxylin A; DF: Donafenib; OA + DF: Oroxylin A + donafenib.